Trump Dumps Industry-Supported Trans-Pacific Partnership

In an executive memorandum, President Trump formally pulled the US out of the Trans-Pacific Partnership (TPP) trade agreement that had been negotiated with 11 other countries and strongly supported by the device industry. Medtech industry groups tried to put a good face on things, saying they look forward to working with the new administration on bilaterial agreements to further open markets in Asia and elsewhere.

President Trump made the US abandonment of the device-industry-supported Trans-Pacific Partnership (TPP) official on Jan. 23 when he directed the US Trade Representative to withdraw from the TPP negotiations and agreement. But the medtech industry is so far signaling public support for the administration as companies watch out for next steps.

The move was, to some extent, symbolic, since Congress had no plans to approve the deal. It follows through on...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from United States

  • Global Medtech Guidance Tracker: September 2024

     
    • By 

    Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

  • Senseonics Readies For US Launch Of 'World’s First One-Year CGM'

     

    US FDA has greenlighted Senseonics’ Eversense 365 continuous glucose monitor, which must be replaced just once a year. Capable of being integrated with compatible insulin pumps as part of an automated insulin delivery system, the fully implantable device lasts 185 days longer than the Eversense E3 sensor and far outstrips competing CGMs, which last only for 10-14 days.

  • Does SCOTUS Chevron Decision Tip The Scales In Favor Of Industry?

     

    With the reversal of the Chevron doctrine in June, lower courts will now have more say in deciding regulatory statutes when the language is murky. But will that open the door to more legal challenges from the healthcare industry against government regulations it finds unfavorable? A pair of legal experts recently discussed the potential implications of the Court’s decision.

  • FDA Releases Six More De Novo Summaries

     
    • By 

    The US FDA released six more device classifications in early September, including products from Edwards, Interscope, and Baxter Healthcare.

More from North America